Amrutanjan Health Care Ltd
Amrutanjan Health Care Ltd Q4 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Amrutanjan Health Care Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY25 Net Sales: Rs. For Q4 FY25: - Net Sales: Rs.
From Amrutanjan Health Care Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 Net Sales: Rs. 135.41 Cr, up 6.57% YoY (Q4 FY24: Rs. 127.06 Cr)
- Q4 FY25 Profit Before Tax: Rs. 20.86 Cr, up 6.43% YoY (Q4 FY24: Rs. 19.60 Cr)
- Q4 FY25 Profit After Tax: Rs. 15.18 Cr, up 11.13% YoY (Q4 FY24: Rs. 13.66 Cr)
- Q4 FY25 OTC Net Sales (including Comfy): Rs. 117.24 Cr, up 13.84% YoY (Q4 FY24: Rs. 108.37 Cr)
- Q4 FY25 Comfy Net Sales: Rs. 34.46 Cr, up 8.18% YoY (Q4 FY24: Rs. 30.27 Cr)
- Q4 FY25 Beverages Net Sales: Rs. 17.67 Cr, up 0.37% YoY (Q4 FY24: Rs. 18.67 Cr)
- Q4 FY25 Electro Plus Net Sales: Rs. 16.20 Cr, up 0.37% YoY (Q4 FY24: Rs. 16.14 Cr)
- FY25 Net Sales: Rs. 451.82 Cr, up 7.26% YoY (FY24: Rs. 421.23 Cr)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY25 investor presentation — and how it ranks against sector p
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presenta
- Kopran Ltd (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key investor presentation takeaways from Kopran Ltd's Q4 FY25 investor presentation — and how it ranks against sector peers.
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q4 FY25 results?
Q4 FY25 Net Sales: Rs. For Q4 FY25: - Net Sales: Rs.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
The investor presentation does not provide any specific details on capex, capacity expansion, new plant, or projects including amounts, status, or timelines.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.